Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma

Author's Avatar
May 25, 2021

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields (TTFields) together with GT Medical Technologies’ GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma (GBM). Novocure’s TTFields are electric fields that disrupt cancer cell division. GammaTile is an FDA-cleared therapy for the treatment of all types of brain tumors.